J&J Ties Up With India's Emcure For a Splash Into Branded Generics; Deal May Be Precursor To Bigger Global Presence
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - It may be a small start in India but the drugs-to-diagnostics giant Johnson & Johnson looks set for a big splash in branded generic drugs - a segment its bigger rivals like Pfizer, GlaxoSmithKline and Sanofi-Aventis have been embracing over the last few years through aggressive partnerships and acquisition of strong regional players